AKT Inhibition in Prostate Cancer — Proceedings from a Session Held Adjunct to the 2026 ASCO Genitourinary Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Overall Survival and Secondary Endpoints
Karim Fizazi notes immature OS data, trends favoring capivasertib, and symptomatic skeletal event delay.
Play episode from 43:25
Transcript
